Herzinfarkt in der Notfallmedizin – Update zu Management und Therapie

Sebastian Keil; Holger Thiele

doi:10.1055/s-0042-123110

Notfallmedizin up2date, Table of Contents

Notfallmedizin up2date 2017; 12(02): 159-170
DOI: 10.1055/s-0042-123110

Internistische Notfälle

Georg Thieme Verlag KG Stuttgart · New York

Herzinfarkt in der Notfallmedizin – Update zu Management und Therapie

Sebastian Keil

,

Holger Thiele

Abstract

All articles of this category

Das akute Koronarsyndrom (ACS) stellt unverändert eine der häufigsten Diagnosen dar, mit denen das Rettungsdienstpersonal konfrontiert wird. Das Management des ACS beginnt mit dem ersten medizinischen Kontakt durch den Notarzt bzw. das Rettungsdienstpersonal. Für alle Entitäten des Herzinfarktes ist die invasive Diagnostik mit Revaskularisation mittels perkutaner Koronarintervention (PCI) entscheidend für die Prognose.

Schlüsselwörter

akutes Koronarsyndrom - Herzinfarkt - Myokardinfarkt - prähospitale Therapie - Door-to-Balloon-Zeit

Full Text

References

Literatur
1 Schnoor J, Gillmann B, Pavlakovic G. et al. Einsatzcharakteristik wiederholter Notarzteinsätze. Notarzt 2006; 22: 141-146
2 McManus DD, Gore J, Yarzebski J. et al. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med 2011; 124: 40-47
3 Roffi M, Patrono C, Collet JP. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267-315
4 Steg PG, James SK, Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619
5 Windecker S, Kolh P, Alfonso F. et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-2619
6 Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Steg PG, James SK, Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619
7 Windolph J, Eitel I, Thiele H. Chest Pain Units. Notfallmedizin up2date 2015; 10: 321-336
8 Thygesen K, Alpert JS, Jaffe AS. et al. Third universal definition of myocardial infarction. Eur Heart J 2012; 33: 2551-2567
9 Wijesinghe M, Perrin K, Ranchord A. et al. Routine use of oxygen in the treatment of myocardial infarction: systematic review. Heart 2009; 95: 198-202
10 Stub D, Smith K, Bernard S. et al. Air versus oxygen in ST-segment-elevation myocardial infarction. Circulation 2015; 131: 2143-2150
11 Nehme Z, Stub D, Bernard S. et al. Effect of supplemental oxygen exposure on myocardial injury in ST-elevation myocardial infarction. Heart 2016; 102: 444-451
12 Steg PG, James SK, Gersh BJ. 2012 ESC STEMI guidelines and reperfusion therapy: Evidence-based recommendations, ensuring optimal patient management. Heart 2013; 99: 1156-1157
13 Kubica J, Adamski P, Ostrowska M. et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J 2016; 37: 245-252
14 Hobl EL, Stimpfl T, Ebner J. et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2014; 63: 630-635
15 Giannopoulos G, Deftereos S, Kolokathis F. et al. P2Y12 receptor antagonists and morphine: A dangerous liaison?. Circ Cardiovasc Interv 2016;
16 Chatterjee S, Chaudhuri D, Vedanthan R. et al. Early intravenous beta-blockers in patients with acute coronary syndrome–a meta-analysis of randomized trials. Int J Cardiol 2013; 168: 915-921
17 Mateos A, García-Lunar I, García-Ruiz J. et al. Efficacy and safety of out-of-hospital intravenous metoprolol administration in anterior ST-segment elevation acute myocardial infarction: insights from the METOCARD-CNIC trial. Ann Emerg Med 2015; 65: 318-324
18 Roolvink V, Ibáñez B, Ottervanger JP. et al. Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention. J Am Coll Cardiol 2016; 67: 2705-2715
19 Montalescot G, Wiviott SD, Braunwald E. et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373: 723-731
20 Steg PG, James S, Harrington RA. et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A platelet inhibition and patient outcomes (PLATO) trial subgroup analysis. Circulation 2010; 122: 2131-2141
21 Montalescot G, van ʼt Hof AW, Lapostolle F. et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; 371: 1016-1027
22 Montalescot G, Bolognese L, Dudek D. et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013; 369: 999-1010
23 Shahzad A, Kemp I, Mars C. et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014; 384: 1849-1858
24 Valgimigli M, Frigoli E, Leonardi S. et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 2015; 373: 997-1009
25 Cavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet 2014; 384: 599-606
26 Eitel I, Desch S, De Waha S. et al. Long-term prognostic value of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. Heart 2011; 97: 2038-2045
27 Eitel I, Desch S, Fuernau G. et al. Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. J Am Coll Cardiol 2010; 55: 2470-2479
28 Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death: myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation 1977; 56: 786-794
29 Terkelsen CJ, Lassen JF, Norgaard BL. et al. Reduction of treatment delay in patients with ST-elevation myocardial infarction: impact of pre-hospital diagnosis and direct referral to primary percutaneous coronary intervention. Eur Heart J 2005; 26: 770-777
30 Terkelsen CJ, Sorensen JT, Maeng M. et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA 2010; 304: 763-771
31 Palmerini T, Biondi-Zoccai G, Della Riva D. et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: Evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 2013; 62: 496-504
32 Jang JS, Jin HY, Seo JS. et al. The transradial versus the transfemoral approach for primary percutaneous coronary intervention in patients with acute myocardial infarction: a systematic review and meta-analysis. EuroIntervention 2012; 8: 501-510
33 Mehta SR, Jolly SS, Cairns J. et al. Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. J Am Coll Cardiol 2012; 60: 2490-2499
34 Valgimigli M, Gagnor A, Calabró P. et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet 2015; 385: 2465-2476